Ticker Details
Ocular Therapeutix, Inc. Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
IPO Date:	July 25, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.25B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 3.66%
Avg Daily Range (30 D):	$0.28 | 3.13%
Avg Daily Range (90 D):	$0.31 | 3.40%

Institutional Daily Volume
Avg Daily Volume:	.98M
Avg Daily Volume (30 D):	2.44M
Avg Daily Volume (90 D):	3.04M

Trade Size
Avg Trade Size (Sh.):	128
Avg Trade Size (Sh.) (30 D):	95
Avg Trade Size (Sh.) (90 D):	108

Institutional Trades
Total Institutional Trades:	1,751
Avg Institutional Trade:	$2.05M
Avg Institutional Trade (30 D):	$2.76M
Avg Institutional Trade (90 D):	$2.37M
Avg Institutional Trade Volume:	.21M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.45M
Avg Closing Trade (30 D):	$4.22M
Avg Closing Trade (90 D):	$3.68M
Avg Closing Volume:	250.72K

News

Jul 3, 2026 @ 1:59 PM Diabetic Retinopathy Pipeline Insight 2026: Compre... Source: Researchandmarkets.Com

Jul 1, 2026 @ 11:00 AM Ocular Therapeutixâ„¢ to Participate in July S... Source: Not Specified

Jun 15, 2026 @ 8:10 PM Ocular Therapeutix vs. Prime Medicine: Which Healt... Source: Pamela Kock

May 19, 2026 @ 5:06 PM What This Fund’s $14 Million Ocular Therape... Source: Jonathan Ponciano

Apr 22, 2026 @ 11:00 AM Ocular Therapeutixâ„¢ to Host Investor Day on ... Source: Not Specified

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.44	$-.4	$-.27
Diluted EPS	$-1.44	$-.4	$-.27
Revenue	$52.04M	$10.79M	$13.25M
Gross Profit	$45.4M	$9.46M	$11.66M
Net Income / Loss	$-290.5M	$-88.61M	$-64.65M
Operating Income / Loss	$-299.44M	$-93.34M	$-69.76M
Cost of Revenue	$6.64M	$1.33M	$1.59M
Net Cash Flow	$317.02M	$-70.36M	$392.29M
PE Ratio